Brepocitinib is an oral drug that inhibits certain enzymes involved in inflammation—called tyrosine kinase 2 and Janus kinase 1—and is being tested for the treatment of several immunological diseases. A phase IIb randomized ...
May 17, 2023
0
2
A new prostate cancer therapy in clinical trials could treat patients resistant to treatment through targeting the disease on a molecular level, based on new Cleveland Clinic research.
Jan 17, 2023
0
29
Children and adults with a rare type of soft tissue cancer will now have a new treatment option that could have a big impact.
Jan 2, 2023
0
4
Tyrosine kinases are enzymes that play central roles in signaling by cytokines involved in the pathogenesis of autoimmune diseases, including lupus. A recent phase 2 clinical trial published in Arthritis & Rheumatology has ...
Nov 12, 2022
0
5
More than 40 years into the HIV pandemic, scientists are still turning up clues revealing how the virus hijacks its host's cellular processes to support its own replication—and promote the long-term survival of the virus ...
Kinase activity is frequently altered in renal cell carcinoma (RCC), and tyrosine kinase inhibitors (TKIs) are part of the standard treatment strategy in patients with metastatic disease. However, there are still no established ...
Aug 17, 2022
0
15
Patients seeking to purchase chemotherapy drugs online face a confusing array of websites, over half of which potentially operate unsafely or illegally, finds a new study in the July 2022 issue of JNCCN—Journal of the National ...
Jul 28, 2022
0
14
Patients with advanced kidney cancer who received a new combination treatment reported health-related quality of life outcomes that were either similar or improved, compared to patients who received standard first-line therapy, ...
Jun 24, 2022
0
80
Patients with severe COVID-19 who were given imatinib had lower mortality rates at 90-day follow-up, according to research published at the ATS 2022 international conference.
May 18, 2022
0
2
Recent findings in the laboratory of University of Kentucky Markey Cancer Center researcher Christine Brainson, Ph.D., could lead to promising treatments for two molecular subtypes of lung cancer.
Feb 10, 2022
0
11
